Frontotemporal lobar degeneration (FTLD) is a group of disorders that principally affect the frontal and temporal lobes of the brain. In many parts of the world, FTLD is rapidly becoming a serious health burden on society and, as a result, the molecular mechanisms that underlie its onset and development have been the target of intense research efforts in recent years. Nonetheless, despite crucial pathological and genetic discoveries in this area much is still uncertain about how the many genes associated with this disease cause the observed neurodegeneration. Moreover, it has not been easy to define the molecular mechanisms that account for the clinical and pathological heterogeneity of the various FTLD subtypes, characterized by aggregates of Tau, TAR-DNA-Binding Protein-43 (TDP-43), and less often Fused in Sarcoma (FUS) protein. In this review, we will examine some of the emerging discoveries in this field: from the recent importance of autoimmunity to the presence of substantial variations in the composition and localization of TDP-43 and FUS brain aggregates in patients, and how they might affect the course of the disease. All together, these new results demonstrate how the observed clinical heterogeneity underlies considerable complexity at both the molecular and the disease pathway level. A better characterization of all this complexity will be essential for a more accurate stratification of patient cohorts for further studies and, eventually, for trials of therapy.
Introduction
Frontotemporal lobar degeneration (FTLD) is defined by the degeneration of the frontal and temporal lobes of the brains, an event that eventually leads to language impairment as well as behavioural and personality changes. At the clinical level, most cases of frontotemporal dementia (FTD) can be included in three syndromes that are referred to as behavioural variant FTD (bvFTD) and two types of primary progressive aphasias (PPAs), the semantic variant of PPA (svPPA) and the agrammatic variant of PPA (avPPA) [1] . In recent years, several reviews have addressed the genetics and clinico-pathological perspective of this disease and for this reason, they will not be the primary focus of this review [1] [2] [3] [4] . Currently, there are no FDA approved treatments for FTD and available treatments mostly involve symptomatic therapies for other disorders [5] [6] [7] .
Considering that FTLD cases represent a clinical spectrum of disorders, genetic findings have identified a number of genes mostly connected with "pure" FTLD (Microtubule-Associated Protein Tau (MAPT) and Granulin (GRN) genes) or genes that can be either connected with both FTLD and ALS: namely TAR-DNABinding Protein-43 (TARDBP), Fused in Sarcoma (FUS), Valosin-Containing Protein (VCP), Charged multivesicular body protein 2B (CHMP2B), Chromosome 9 Open Reading Frame 72 (C9orf72), Optineurin (OPTN), Sequestosome-1 (p62/SQSTM1) and Ubiquilin-2 (UBQLN2) [8, 9] .
At present, the greatest difficulty in trying to understand the pathological mechanisms of FTLD is the presence of many disease and modifier genes that together explain approximately 50% of the familial FTLD patients but less than 10% of the sporadic FTLD patients [9] . It is expected that different combinations of the known risk genes together with still-to-be-discovered genes/factors will probably account for the remaining patients. Nonetheless, the genes identified so far have already provided a wealth of information regarding the pathways, regulated by these genes, that become altered in disease ( Figure 1 ).
FTLD molecular pathology
In contrast to the genetics, from the histological point of view, FTLD seems to be less complex, with three major types of aggregated proteins described: Tau, TDP-43 and FUS. As a result, all these clinical syndromes can fit in four different pathological categories depending on the type of protein that is found aggregated in the brain. Accordingly, on the basis of the molecular pathology, these four categories are currently referred to as FTLD-Tau, FTLD-TDP, FTLD-FUS and FTLD-UPS [4] . In addition to these major protein signatures, however, it should now also be noted that approximately 10-20% of all FTLD-TDP cases display inclusions made up by RNA foci and dipeptide-repeat protein species (DPRs) that are produced following unconventional translation of a G 4 C 2 hexanucleotide expansion in the C9orf72 gene [10] [11] [12] . In these cases, both the sense and antisense repeats are unconventionally translated leading to the synthesis of poly-GA, poly-GP, poly-GR dipeptides for the sense orientation and poly-PR, poly-PG and poly-PA dipeptides for the antisense orientation. The pathological significance of these inclusions is still the subject of debate but the findings of several groups are all consistent in proposing that certain DPR proteins are toxic, especially the poly-PR and poly-PA species [13] .
Tau protein is the principal component of the neurofibrillary tangles that occur in approximately 45-50% of all FTLD patients [14] and mutations in this gene that are highly disease-associated soon established a direct link between this protein and the pathology [15] [16] [17] . According to modern nomenclature, these cases are referred to as FTLD-Tau. The other two major types of histology found in the brain of FTD patients, on the other hand, consist of two RNA-binding proteins known as TDP-43 and FUS.
Briefly, the Tau protein binds and stabilizes microtubules (MTs) in neurons, a process that is highly regulated by phosphorylation and acetylation [18] . Mutations in this protein either alter the protein sequence by introducing missense mutations that reduce the ability of the protein to bind microtubules or increase fibrillization ability. Many MAPT mutations have also been shown to occur in the exonic and intronic region downstream of the pre-mRNA splicing donor site of Tau exon 10 [19] . These mutations, although they do not alter the protein sequence, have been shown to affect the alternative splicing of exon 10 and regulates the ratio of isoforms that contain three (3R) or four (4R) of the microtubule-binding repeat coded by this exon. As a result of these changes, in both sporadic and familial forms of FTLD-Tau, this protein forms filamentous aggregates in neurons and glia. These inclusions are the pathological hallmark of the disease and cause multiple kinds of cell dysfunction such as abnormal proteostasis due to inhibition of the Ubiquitin-Proteasome System (UPS), and impaired axonal transport and mitochondrial functionality [6] (Figure 1) . As a series of reviews in this journal has been recently dedicated to Tauopathies [20] , the focus of this article will be the involvement of TDP-43 and FUS proteins in FTLD, the aspects that may differentiate the role of these proteins in FTLD from ALS, and on emerging pathological mechanisms such as autoimmunity.
The involvement of TDP-43 in FTLD was first described in 2006 when this protein was reported as the main component of the characteristic aggregates in the affected neurons of patients with ALS and FTLD [21, 22] . In 2009, this discovery was followed by the identification of FUS, as another common and abundant RNA-Binding Protein (RBP) involved in the pathobiology of subsets of familial ALS and sporadic FTLD cases [23, 24] . Since then, the basic properties of both proteins have been under intense study and their potential role in disease has been recently reviewed in many reports [25] [26] [27] .
At the structural level, both TDP-43 and FUS belong to a class of nuclear factors known as heterogeneous ribonuclear proteins (hnRNPs). This is a very ancient and conserved family of proteins and its members have the function of binding nascent RNA molecules as soon as they are transcribed. In this way, they form an extensive protein-protein and protein-RNA network that allows the cell to regulate all the processing steps (splicing, editing, surveillance, stability and transport) that are required in order to achieve proper mRNA expression [28] . Over the years, considerable evidence has steadily accumulated that alterations in hnRNP proteins are a major disease pathway in the ALS/FTLD spectrum [21, 29] . More recently, the discovery that hexanucleotide repeat expansions in the C9orf72 gene is the most frequent mutation associated with familial ALS and FTLD [13] has clearly suggested that many types of alterations can also occur at the level of RNA metabolism in addition to variation in gene expression or alternative splicing processes (i.e. RNA toxicity, RBP sequestration, production of dipeptide repeated proteins from nonconventional translation pathways and haplotype insufficiency). The fact that all these proteins are currently recognized as major players in the onset of many neurodegenerative diseases opened several new promising pathways to develop therapeutic strategies aimed at slowing-down or even preventing the neuronal death characteristic of this type of diseases [30] .
General overview of FTLD pathological mechanisms
At present, there are several converging molecular mechanisms associated with the ALS/FTLD spectrum that could work in an interconnected manner (Figure 1) [31, 32] . At their initial stages, these mechanisms mostly involve RNA-processing defects, RNA toxicity and impaired protein homeostasis [33] . Once the normal working of these basic processes is disrupted, this is then reflected in the viability/efficiency of other pathways such as nucleo-cytoplasmic transport of mRNAs and proteins [34, 35] , protein translation [36] or stress granule dynamics [37, 38] . Eventually, the damage spreads to various cellular organelles such as the Endoplasmic Reticulum (ER) and mitochondria [39, 40] and this eventually leads to the premature death of the affected neurons as schematically summarized in Figure 1 .
One of the major pathways that lies at the heart of FTLD pathology is a defect of cellular clearance mechanisms, such as the autophagy-lysosome system or the ubiquitin-lysosome system [41, 42] . These mechanisms have the job of degrading misfolded/aggregated proteins and there is considerable genetic evidence that supports their important role in neurodegeneration in general [41] . Although quite rare, the occurrence of mutations in genes encoding for proteins in these pathways such as VCP, CHMP2B, TBK1, OPTN, p62/SQSTM1 and UBQLN2 is closely associated with disease development [43] . Specifically, all these proteins play key role in various aspects of misfolded protein degradation such as in autophagosome-autolysosome maturation (controlled by VCP), late-stage endosome-lysosome fusion (controlled by CHMP2B), phosphorylation of autophagy adaptors p62 and OPTN (controlled by TBK1), autophagosome formation and maturation (controlled by OPTN), autophagy receptor (controlled by p62/SQSTM1) and recruitment of autophagosomes to polyubiquitinated aggregates. Impairment of degradation may lead to the aggregation of the major pathological proteins such as Tau, TDP-43 or FUS with additional consequences on microtubule stability (in the case of Tau) or alterations at the level of RNA metabolism (in the case of TDP-43 and FUS) [44] [45] [46] . In addition to their aggregation, following defects in the protein clearance mechanisms, a causative role in FTLD/ALS can also be associated with the occurrence of mutations in several other cellular RBPs such as hnRNP A2/B1, hnRNP A1, and the FET family of DNA and RNA-binding proteins that includes FUS, EWS (Ewing Sarcoma) and TAF15 (TATA Binding-Associated Factor 15) [30, [47] [48] [49] . It has also become clear in recent years that many of them share the common feature of undergoing liquid-liquid phase separation (LLPS) due to the presence of a low-complexity sequence domain (LCD) within their amino acid sequences. In normal conditions, LLPS modifies their normal function within cells by regulating their recruitment in membrane-less organelles such as stress granules. However, recent studies have shown that dysregulation of this process can also affect their propensity to aggregate in disease [50] . In particular, disease mutations in several of these proteins such as hnRNP A1 [51] , TDP-43 [52] and FUS [53] can change their ability to form liquid droplets in stress conditions, eventually leading to aberrant aggregation.
Interestingly, it has been recently reported that the type of lysosomal impairment may be important in determining the type of aggregates in patient brains. Specifically, the occurrence of FTLD-Tau may lie with a relative deficiency of lysosomes, or defective vesicular transport, whereas the occurrence of FTLD-TDP may be more connected with lysosome dysfunction rather than a lack of available lysosomes or degradative enzymes [54] . What is nonetheless emerging clearly from all these studies is that protein clearance defects, RBP proteins, and RNA repeats act in a combinatorial fashion, and that their relative abundance and dosage can significantly affect the functions of the major players, such as TDP-43 and FUS. This conclusion is supported by the observation that many of these proteins belonging to the autophagic and lysosomal pathways are directly connected with TDP-43 by protein-protein interaction (see Table 1 ).
One issue that is still debated is whether these FTLD pathological mechanisms act through gain-or loss-offunction effects [27, 55] . Loss-of-function effects would be mediated by the aberrant aggregation of the disease protein to the extent that it will impair their normal functions within the cell. On the other hand, gain-of-function might result from direct toxicity of the aggregates, increased production of protein above physiological levels, or aberrant functional properties following the introduction of mutations. Of course, both mechanisms are not mutually exclusive and, for TDP-43, there is substantial evidence that supports the presence of both gainand loss-of-function effects within neurons [56] .
Interestingly, the same kind of considerations applies to several other FTLD-associated proteins, such as FUS, that may cause disease through toxic gain-of-function mechanism [57, 58] or loss-of-function effects deriving from dysregulation of RNA-processing events as a consequence of its aberrant aggregation [59, 60] . Notably, both mechanisms may work simultaneously and involve paraspeckle formation [61] . Finally, compared to TDP-43 and FUS, less is known about the mechanisms of pathogenicity of EWS and TAF15 in FTLD. Overexpression of EWS in Drosophila disease models is toxic and its disease-associated mutations aggregate more rapidly compared to wild-type protein [62] . Likewise, TAF15-associated mutants have been shown to have a higher propensity to localize in the cytoplasm compared to wild-type protein [63] . Therefore, it would seem that at least for these two proteins, existing evidence would support a gain-of-function mechanism. Nonetheless, eventual loss-of-function effects will need to be evaluated in future research. The reason is because TAF15 has been found to bind a very high number of RNA transcripts in common with FUS [64, 65] , suggesting that TAF15 nuclear absence can also result in RNA-processing alterations affecting neuronal survival.
Most importantly, it should be noted that the molecular pathology of FTLD is very much a fast-moving field. For many years, it was considered that the frontotemporal regions were the most affected regions in FTLD patients. However, several MRI studies have shown that the caudate nucleus might also be significantly affected in the early stages of FTLD/ALS and associated with cognitive involvement [66] . Likewise, bioinformatic approaches that have used current functional knowledge to build an integrated FTLD protein network suggest that, in addition to well-known processes ( Figure 1 ), there are also some potentially new mechanisms such as DNA damage response [67] . The reason this response may be important is because maintaining the integrity of genomic DNA in postmitotic neurons is particularly critical, as it has to be preserved for the entire life of an individual. At present, there are many connections between altered expression 
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Binding of TDP-43 to UBQLN 2 occurs through the C-terminus and can be inhibited by 4-aminoquinolines. UBQLN2-positive inclusions were identified in spinal cord sections of patients with X-linked ALS and found to colocalize with ubiquitin, p62, TDP-43, FUS and OPTN but not SOD1. TDP-43 has also been reported to colocalize with Ubiquilin-2 in skin patient fibroblasts following MG132 and SA treatment. The expression of UBQLN2 ALS-associated mutant P506T in mouse primary neuroglial structures and developing neonatal brains also colocalizes with TDP-43.
[ [160] [161] [162] [163] of FTLD-associated proteins and alterations in this process. First and foremost, the FUS protein has been long known to play a role in the DNA damage response [68] and FUS disease-associated mutants show deficient ability to repair DNA double-stranded breaks (DSBs) [69] . Second, recent findings indicate that TDP-43 is capable of inducing neurodegeneration due to impaired chromatin dynamics through compromised function of the chromatin remodeller Chd1/CHD2 that prevents appropriate expression of protective genes [70] . Accordingly, overexpression of TDP-43 in Drosophila results in cell death due to many alterations, including DNA damage [71] . Finally, overexpression of poly-GR repeats in neurons is also able to induce DNA damage although the exact mechanism has not been clarified [72, 73] . Nonetheless, all this experimental evidence suggests that DNA damage contributes to FTLD together with the other mechanisms described above ( Figure 1 ). Among all these potential newcomers, another area that is actively growing is the increasing connections between FTLD and autoimmune diseases.
Autoimmunity in FTLD
In recent years, the susceptibility of the frontotemporal areas in autoimmune central nervous system disorders has been increasingly reported in paraneoplastic syndromes, linked to the presence of a specific systemic cancer or in autoimmune encephalitis (AIE), with antibodies directed towards the extracellular domain of surface neuronal proteins. Limbic encephalitis is a condition with a subacute onset of short term memory loss, behavioural changes and seizures, mainly involving the temporo-medial lobes and the amygdalae, which clinically resembles FTLD [74] . Also comparison among brain magnetic resonance analyses and positron emission tomography (PET) imaging provided hints for differences and similarities in AIE and FTLD, with structural MRI showing the involvement of the same brain regions, and PET imaging demonstrating an activation of microglia as the result of a neuroinflammatory process associated with FTD neurodegeneration [75, 76] . Over time, different types of neuronal antibodies associated with AIE have been identified, the first of which was against GluR3, followed by discoveries of antibodies directed against voltage-gated potassium channels (VGKC-Abs), the N-methyl-D-aspartate subtype of ionotropic glutamate receptors (NMDAR) and several others autoantibodies [77] [78] [79] . The first autoimmune process linked to neurodegeneration is the identification of IgLON5-antibody in patients with atypical Parkinsonism and Tau protein aggregation [80] . In FTLD, a few observations have also argued for an immune system involvement: (1) increased intrathecal inflammatory cytokines have been detected [81] ; (2) a close but not significant association with thyroid disease [82] ; (3) a significant enrichment for elements of the immune system implicated in antigen presentation, including the HLA-DR5 locus [83, 84] and, more recently, (4) the detection of anti a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor 3 (GluA3) antibodies in serum as well as in cerebrospinal fluid (CSF) from a large clinical series of FTD [85] .
Heterozygous mutations in triggering receptor expressed on myeloid cells 2 (TREM2), which is a key modulator of host immune responses, are also known to increase the risk for various neurodegenerative disorders, including FTLD [86] . In the central nervous system, TREM2 is exclusively expressed by microglia and mutations in this gene likely confer loss of TREM2 protein function, thereby leading to altered microglial survival, phagocytosis and inflammatory response [86] . Loss of TREM2 causes impaired microglial responses to injury and signals implicated in chemotaxis [87] . Moreover, TREM2 T66M knock-in mouse models have been shown to generate a selective dysfunction in microglia and aberrant glucose metabolism of the frontal lobes [88] .
The role of TDP-43 in the immunological hypothesis has been hypothesized following the observation of a higher prevalence of a large variety of autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, psoriasis and Sjogren syndrome, in the svPPA, as well as in FTLD patients bearing a pathogenic mutation in GRN gene, both conditions being selectively characterized by TDP-43 deposits [83] . In addition, plasma Tumour necrosis factor alpha (TNFalpha) levels were significantly increased compared to control subjects, in the svPPA and GRN cohorts further strengthening the hypothesis that an autoimmune process might sustain these FTLD-TDP pathologies [83] . A genetic mouse model of the Q331K TDP-43 mutation responsible for ALS also has an up-regulated complement response that supports this view [89] .
Mutations in GRN are a frequent cause of monogenic FTLD-TDP and the GRN mutations are null mutations leading to haploinsufficieny. GRN is a microglialexpressed gene and the progranulin protein was first characterized as an inflammatory agent engaged in wound response [90] . Interestingly, using protein microarrays of human cDNA expression libraries, antibodies against PGRN were found in sera from patients with an autoimmune disease, and in the same anti-PGRN positive patients, lower PGRN plasma levels were observed, probably occurring via hyperphosphorylation pathways [91, 92] . In line with data from GRN knockout mice, the absence of PGRN caused a progressive up-regulation of genes associated with lysosomal function and innate immune response genes, including complement activation and ultimately leading to an increase of synaptic pruning [93] . Paralleling that observed in GRN knockout mutant mice, increased levels of activated complement (C1qa and C3b) were detected in CSF from FTLD patients bearing GRN mutations [93] . Selective deletion of GRN in mice microglia generated excessive obsessive-compulsive behavioural disorders, which were rescued by inactivation of nuclear factor jB (NF-jB) and TNF-alpha [94] . We can therefore hypothesize that in FTLD, PGRN haploinsufficiency by the dysregulation of microglial complement repertoire and loss of synaptic pruning and lysosome maturation may eventually lead to TDP-43 aggregation. For this reason, targeting neuroinflammation by using selective agents able to suppress the activation of NF-jB and to reduce TNF-alpha levels may be effective in the treatment of FTD patients [95] .
In a similar way, a high prevalence of autoimmune disorders was found within C9orf72 and FTD/MND cohorts [96] . Moreover, the C9orf72 gene which expansion is known to cause FTLD and ALS by a mechanism associated to TDP-43 deposition, is strongly linked to immune system: C9orf72 null mice rather than a neurodegenerative process, develop progressive splenomegaly and lymphadenopathy, altered splenic myeloid cell populations, increased levels of circulating proinflammatory cytokines, and in some colonies a fulminant autoimmune disorder [97] . C9orf72-deficient mice developed mild age-related neuroinflammation showing lysosomal accumulation and a proinflammatory phenotype with increased expression of interleukins IL-6 and IL-1b [98] .
One outstanding question is how neuronal antigens may undergo immune exposure. In this respect, recent findings provided evidence that the Blood-Brain Barrier (BBB) is an adjustable system, as the activation of adenosine receptors or CD39/CD73 expression may alter the BBB permeability [99] . In animal models of autoimmune encephalomyelitis, extracellular adenosine positively regulates the migration of lymphocytes into the central nervous system, with adenosine receptor-deficient mice developing only very mild signs of autoimmune encephalomyelitis [100] . The mechanism underlying BBB alterations are still to be completely elucidated, although recent data showed that neuroinflammation is linked to the symptomatic phase of the neurodegenerative process, affecting both sporadic and genetic cases, but with different pathways in ALS and FTLD [101] . Nonetheless, it can be suggested that reversible changes in the BBB can result in the temporary exposure of specific antigens to the immune system that will trigger an autoimmune response that may eventually lead to TDP-43 deposition.
Specific TDP-43/FUS alterations in FTLD
Although TDP-43 and FUS pathologies are common for both ALS and FTLD, there are also an increasing number of observations that find distinct differences between the inclusions found in patients affected by different subtypes of FTLD.
For example, immunostaining of EWS and TAF15 proteins can be used to efficiently differentiate ALS-FUS and FTLD-FUS cases [102] . In fact, in FTLD the FUSpositive inclusions in the cytoplasm can be labelled also with TAF15 and EWS antibodies, and this is accompanied by a reduction in the normal nuclear staining of all FET proteins. In contrast, in cases of ALS-FUS, TAF15 and EWS remain localized to the nucleus and do not label FUS-positive inclusions. Furthermore, in addition to FET proteins, the presence of hnRNP A1 was also found in FUS neuronal cytoplasmic inclusions and dystrophic neurites of patients diagnosed with the very rare neurological disorder known as neuronal intermediate filament inclusion disease (NIFID) [103] and have also been observed in atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions (aFTLD-U) [99] . In keeping with this finding, a direct comparison of the FUS pathology that characterizes the three major FTLD-FUS subtypes (aFTLD-U, NIFID and basophilic inclusion body disease, BIBD) has shown significant similarities but also differences in the morphology of the FUS inclusion of these patients. Among them, one of the most striking features is the complete absence of FUS neuronal intranuclear inclusions in patients diagnosed with BIBD compared to aFTLD-U and NIFID cases [104] .
At present, no studies have focussed on the consequences at the molecular level of the presence vs. absence of FET proteins, of hnRNP A1, or of cytoplasmic vs. nuclear localization of FUS aggregates. However, these differences certainly suggest the existence of different pathological processes between different subtypes even if they share the same basic type of pathology [105] .
The existence of different pathological processes is even more likely for the much higher number of FTLD and ALS patients that share the same basic feature of displaying TDP-43 proteinopathy. In fact, differences have been observed starting from a simple biomarker approach where a systematic review and meta-analyses of previous diagnostic studies have shown that CSF TDP-43 levels are significantly increased in patients with FTLD-ALS spectrum disorder. However, if the data are analysed for ALS and FTLD separately, only patients with ALS (not patients with FTLD) showed a significantly increased amount of TDP-43 [105, 106] . At present, there are no known or suggested molecular mechanisms that can account for this difference, although a recent analysis revealed a trend towards cognitive impairment in ALS patients with greater TDP-43 pathologic burden [107] . Another potentially important difference between TDP-43 inclusions in FTLD-ALS and FTLD-TDP has been observed to occur in the anterior cingulate cortex but not in the motor cortex of affected patients. In particular, significant rounded TDP-43 inclusions and rare circumferential TDP-43 inclusions were identified in the anterior cingulate cortex of FTLD-TDP cases. In contrast, FTLD-ALS cases revealed significant circumferential TDP-43 inclusions and rare rounded TDP-43 inclusions in the anterior cingulate cortex [108] . In this case, the reason for this difference might reside in differential types of post-translational modifications of TDP-43 in this brain region between the two types of patients. In fact, it is now well accepted that TDP-43 can be subject to many different types of post-translational modifications with the principal ones being phosphorylation, acetylation, ubiquitination and disulphide bond formation ( Figure 2) . As recently reviewed, all these modifications can significantly affect several key aspects of TDP-43 such as half-life, dimerization/oligomerization propensity, RNA-binding activity and cellular localization [109] .
In addition to differences between FTLD-TDP and ALS, one of the most intriguing features of FTLD-TDP pathology is that it can be classified into four distinct subtypes according to TDP-43 immunohistochemical profiles [110] . The first, Type A, is the most frequent subtype and displays numerous crescentic to ring-like neuronal TDP-43 cytoplasmic inclusions (NCIs) and dystrophic neurites (DNs) mostly present in superficial neocortical levels. On the other hand, Type B has numerous NCIs in both superficial and deep neocortical layers but with few DNs, whilst Type C is characterized by few NCIs and by DNs predominantly in superficial cortical layers that are often longer and thicker than the ones in type A. Finally, Type D has numerous neuronal intranuclear inclusions (NIIs) and DNs with few NCIs in superficial and deep cortical layers. A detailed table summarizing the properties of all these different FTLD-TDP aggregates can be found in Lee et al. [111] . Another distinguishing feature of these different types of aggregates is the observation that they contain different types of phosphorylated TDP-43 fragments in the 18-26 kDa range [112] . These fragments could play an important role in promoting aggregation of TDP-43, inducing toxicity, and participate in the cell-to-cell spreading of the disease [109, 113] . Finally, a few rapidly progressive FTLD-TDP cases have been very recently described that display a different type of TDP-43 aggregation characterized by granulofilamentous neuronal inclusions and very fine, dot-like neuropil aggregates affecting all neocortical layers together with the presence of curvilinear oligodendroglial inclusions in the white matter. Patients carrying this very peculiar type aggregation have been provisionally named FTLD-TDP Type E pending confirmation and consensus recommendation [111] .
At the molecular level, the presence of these various subtypes is one of the most fascinating and intriguing aspects of FTLD-TDP pathology because their occurrence correlates with the type of disease that patients develop. Specifically, Type A cases have been associated with bvFTD or nonfluent/agrammatic PPA (naPPA), and especially with disease-causing mutations in the GRN gene; Type B neuropathology is mostly associated with bvFTD but also FTLD-MND and with the occurrence of RNA expansion in the C9orf72 gene; Type C cases are associated with bvFTD and svPPA without any particular association with a FTLD-associated gene; whilst Type D cases are exclusively associated in carriers of mutations in the VCP gene that in addition to FTLD can also cause familial Inclusion Body Myositis, Paget's disease of the bone, and multisystem proteinopathy [3] . Finally, the presence of C9orf72 RNA expansions in addition to the TDP-43 pathology seems to clinically correlate with the occurrence of psychosis and obsessivecompulsive disorders at the onset of disease [43] .
At present, there are no clues about the molecular mechanisms that underlie these clinico-pathological correlations. For this reason, an important future area of research will be to discover the reason for these various types of inclusions and try to identify the factors that can induce aggregation with different morphologies, in the cytoplasm vs. the nucleus, or in specific brain regions. These could be due to different post-translational modifications or the selected presence of TDP-43 fragments in these different subtypes. Intriguingly, another possibility is that specific local conditions, such as RNA binding or the presence of DPR repeats from the C9orf72 RNA expansions, might affect the liquid-liquid phase transition [50] of proteins like TDP-43 and FUS. These proteins, in fact, contain an intrinsically disordered domain and have already been shown to undergo this kind of transitions depending on the presence of mutations or other local conditions [52, 114, 115] . In this way, the local context may influence the way these proteins aggregate with consequently differential changes in their pathological effects.
In addition to the main protein itself, another important aspect of FTLD molecular pathology is the frequent colocalization of proteins together with the TDP-43 aggregates in the neurons of affected patients (Figure 2) . This feature could also be an important aspect of disease because all these co-aggregating proteins might participate in the neurodegenerative process, depending on the extent of their "sequestration" from the soluble cellular pool and/or the sensitivity of different types of neurons with regards to their specific role.
For example, cytosolic TDP-43/DISC1 co-aggregates have recently been detected in the brains of both an FTLD mouse model and patients with FTLD [116] . From a pathological point of view, this aberrant co-aggregation was shown to be capable of disrupting the activity-dependent dendritic local translation through impairment of translation initiation and reduced synaptic protein expression that is a typical pathologic feature in many TDP-43 disease models [117] [118] [119] . In addition to DISC1, other factors such as the TTBK1/TTBK2 kinases or the stress granule markers TIA-1/eIF3 have also been shown to colocalize with phosphorylated TDP-43 in human postmortem tissues from both FTLD and ALS cases [120, 121] . From the point of view of a direct connection between this co-aggregating proteins and disease, the presence of TIA1 is particularly important considering that mutations in this factor have been recently associated with altered stress granule dynamics and occurrence of ALS-FTD [122] . Another protein that forms cytoplasmic inclusions in the majority of ALS and FTLD-TDP cases is RBM45, a protein similar in structure to TDP-43 and FUS. In patients, RBM45 colocalizes with TDP-43 in inclusion bodies and was especially present in ALS-FTLD patients with C9orf72 expansions. It was later shown that RBM45 can form homo-oligomers, physically associates with the ALS-linked proteins TDP-43 and FUS in the nucleus, and that its aggregates may lead to mitochondrial dysfunction [123] [124] [125] [126] . At present, not much is known about the functional properties shared by RBM45 with TDP-43 and FUS. However, they probably exist if we consider that RBM45 has also been reported to be able to affect the DNA damage response [127] because it competes with histone deacetylase 1 (HDAC1) for binding to FUS, thereby regulating the recruitment of HDAC1 to DNA damage sites [127] . Finally, there has recently been a report that hnRNP E2 is associated with TDP-43-immunoreactive neurites in svPPA with FTLD Type C inclusions but not with other pathological subtypes of FTLD [128] .
Taken together, all this evidence points to the very likely possibility that different FTLD subtypes might be characterized by a qualitatively different protein composition, especially those belonging to the family of RNA-binding protein family. The presence of some or all of these factors might well result in different pathological end-points in terms of neuronal specificity/toxicity, selective vulnerability of different neuronal population, or in the ability of the aggregated/misfolded proteins to spread from cell-to-cell through a prion-like mechanism [113] .
It is also important to note that all this complexity is not limited to TDP-43. In fact, it has been shown quite recently that C9orf72 RNA foci can colocalize with hnRNP H in patient brains and that as a result hnRNP H splicing targets become disrupted, potentially contributing to the pathology [129] .
As if this were not enough, an additional source of complexity comes from the many factors that can influence the function of TDP-43 and FUS in different cells, even in the absence of direct protein-protein connections or aggregate colocalization. Not surprisingly, the functionality of factors such as TDP-43 can be profoundly affected by variations in expression of similar proteins with which they have evolved together over millions of years, such as hnRNPs. For example, we initially reported that elevated human hnRNP A/B levels in the brain of FTLD-TDP patients may represent a defence mechanism by repressing the inclusion of a TDP43-controlled toxic exon within the Sort1 gene [130] . In addition to this evidence, several other reports have highlighted the ability of hnRNP proteins to modulate TDP-43 toxicity and cellular localization in different experimental systems [131] [132] [133] [134] . Just very recently, it has been shown that hnRNP L can successfully rescue the induction of cryptic exon splicing caused by TDP-43 loss of function [135] .
In conclusion, a growing body of evidence suggests that variation in expression and/or solubility of the many different hnRNP proteins that are abundantly expressed in neuronal cells can strongly modulate pathological effects by acting through common targets/pathways that are connected with the FTLD/ALS spectrum [136] .
Conclusions and future perspectives
From the complex picture described above, it is therefore not so surprising that FTLD is such a heterogeneous disease. The reason for this heterogeneity resides in the complex interplay between many players at different stages of the pathology. In the initial stages, genetic background is probably the most important factor in deciding the most likely type of protein players that will be aggregating in neurons: Tau, TDP-43 or FUS. However, the decision as to when, where, and in which specific form these disease proteins will aggregate in patient brains will very much depend on the level of expression of their own molecular modifiers, comorbidities, or the presence of various specific stressors. In turn, the consequent combinatorial activation of specific pathological pathways will result in individuals to eventually develop particular forms of FTLD and/or display differential severity and disease progression rates.
Considering this complexity, it may therefore seem an almost impossible task to find successful therapeutic options that might benefit all patients affected by FTLD. Not surprisingly, many of the general drugs that target some of the major players in disease (Tau, GRN) have turned out not to be very promising [137] .
However, this does not mean that a careful analysis of the genetics and molecular pathology of FTLD cases might not provide some effective treatments that are specific for efficient conditions. For example, it has been recently reported that FTLD-ALS patients with a C9orf72 mutation had the greatest burden of poly-GR pathology compared to FTLD and ALS patients [138] . This observation, if confirmed, suggests that oligonucleotide antisense therapy [139] against this type of DPR might be more effective in FTLD-ALS patients as opposed to others. Along similar lines, FTLD patients that carry the SIGMAR1 risk locus might benefit from treatment with specific Sigma-1 agonists (Opipramol) or antagonists (AC915, Haloperidol) that can mimic the effects of altered SIGMAR1 expression on TDP-43 localization, with antagonists decreasing TDP-43 cytoplasmic localization and agonists having the opposite effect [140] .
At the moment, what we probably need the most is more basic research aimed at unravelling the role played by different pathways in disease onset/progression and how specific changes in aggregate localization/composition translate at the level of the molecular pathology. These kinds of analyses will be facilitated thanks to the great technical advances in mass spectrometry-based proteomics and transcriptomic approaches [141, 142] . The aim should be to use these approaches on large numbers of patients to detect and categorize the specific RNA and protein alterations in physiological and clinically relevant contexts. In parallel, other essential areas will be to identify patients that will benefit from a given therapy and to identify biomarkers of disease that will facilitate early diagnosis of specific dementia subtypes, predict disease progression, and help evaluating the effectiveness of clinical trials.
By combining these approaches, we will hopefully be able to stratify patients according to an as wide as possible set of genetic and molecular "signatures". This will greatly help finding targeted solutions to lessen disease burden and progression at least in subsets of patients.
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